Kymera Therapeutics, Inc. Analysis
| Analyst Ratings |
|
Average Target Price
|
55.50
|
|
Average Rating
|
4.17
|
|
# Strong Buys
|
9
|
|
# Buys
|
3
|
|
# Holds
|
6
|
|
# Sells
|
0
|
|
# Strong Sells
|
0
|
| Quarterly Earnings History |
| Quarter |
EPS Estimate |
EPS Actual |
EPS Difference |
Surprise Percent |
|
2022-09-30
|
-0.74
|
-0.79
|
-0.05
|
-6.76%
|
|
2022-06-30
|
-0.70
|
-0.78
|
-0.08
|
-11.43%
|
|
2022-03-31
|
-0.66
|
-0.71
|
-0.05
|
-7.58%
|
|
2021-12-31
|
-0.57
|
-0.66
|
-0.09
|
-15.79%
|
|
2021-09-30
|
-0.42
|
-0.56
|
-0.14
|
-33.33%
|
|
2021-06-30
|
-0.29
|
-0.55
|
-0.26
|
-89.66%
|
|
2021-03-31
|
-0.15
|
-0.29
|
-0.14
|
-93.33%
|
|
2020-12-31
|
-0.04
|
-0.29
|
-0.25
|
-625.00%
|
| Annual Earnings History |
| Fiscal Year End |
EPS |
|
2022-12-31
|
-2.28
|
|
2021-12-31
|
-2.06
|
|
2020-12-31
|
-2.06
|